INTRODUCTION
Protein is the main executor of life activity, and maintenance of proper protein homeostasis is essential for cell viability and growth. Protein degradation pathways (ubiquitin-proteasome system and autophagy-lysosomal pathway) and molecular chaperones, which facilitate protein folding, play central roles in maintaining protein homeostasis of living systems. Hsp90 family is a member of molecular chaperone families. And it is specified by assisting the maturation of hundreds of selected client proteins including transcription factors, steroid hormone receptors, and signaling kinases Prodromou, 2016 Prodromou, , 2017 Schopf et al., 2017) . By collaborating to maintain the activity of numerous proteins involved in signaling pathways and cell-cycle control, Hsp90 plays key roles in cellular signal transduction and cell growth.
In eukaryotes, such as S. cerevisiae and Homo sapiens, two cytosolic isoforms of Hsp90 are encoded and expressed: Hsc82 and Hsp82 in S. cerevisiae and Hsp90a and Hsp90b in Homo sapiens. Hsc82 and Hsp90b are constitutively expressed, whereas the levels of Hsp82 and Hsp90a are significantly up-regulated under stressful conditions, including heat shock and hypoxia (Zuehlke et al., 2015) . For the human paralog Hsp90a, pathological changes including cancer can also stimulate its expression (Zuehlke et al., 2015) . Owing to the involvement in cell growth and the up-regulation in multiple types of cancer, Hsp90a is becoming a promising target for anti-cancer drug development (Garg et al., 2016; Prodromou, 2009; Sidera and Patsavoudi, 2014) .
Although Hsp90 homologs are expressed in a variety of organisms from bacteria to mammals, they share similar structure and function ( Figure S1 ) Prodromou, 2016 Prodromou, , 2017 Schopf et al., 2017) . Hsp90 contains three well-defined structural domains: an N-terminal ATP binding domain (NTD) for ATP-binding and hydrolysis, a middle domain (MD) for client protein recognition, and a C-terminal domain (CTD) mediating Hsp90's dimerization. Hsp90 is tightly regulated by endogenous small molecules such as ATP and ADP by binding to its NTD, and co-chaperone proteins (Hop, Hsp70-Hsp90 organizing protein; p23, 23 kDa protein; Cdc37, protein encoded by the cell division cycle 37 gene; and Aha1, activator of Hsp90 ATPase 1) interacting with the subdomains of the chaperone Karagoz et al., 2011; Meyer et al., 2004; Panaretou et al., 2002; Pearl and Prodromou, 2006; Prodromou, 2016 Prodromou, , 2017 Schopf et al., 2017; Siligardi et al., 2002 Siligardi et al., , 2004 Vaughan et al., 2008) . Hsp90 possesses ATPase activity, and the binding and hydrolysis of ATP will drive conformational changes of Hsp90 associated with its different function stages: in the apo state, Hsp90 exists in a ''V''-shaped conformation dimerized via its CTD; with the binding of ATP, a dimerization of Hsp90's NTD occurs, and co-chaperone proteins and client proteins are recruited; with the hydrolysis of ATP and the releasing of ADP, Hsp90 goes back to the apo ''V''-shaped conformation , 2001 Prodromou, 2012; Prodromou et al., 2000; Prodromou and Pearl, 2003) . As mentioned above, tens of co-chaperones are involved in regulating the activity of Hsp90 by interacting with the chaperone protein. For example, the TPR domain (the tetratricopeptide repeat domain) of Hop could interact with the extreme C-terminal MEEVD motif (element containing conserved amino acid sequence of MEEVD) of Hsp90 and the middle domain of Cdc37 could bind to Hsp90 NTD. The binding of either of these two co-chaperones will inhibit Hsp90's ATPase activity and hinder the dimerization of the NTD of the chaperone with the presence of ATP Siligardi et al., 2002; Vaughan et al., 2006; Zuehlke and Johnson, 2010) . p23 is another well-studied inhibitory co-chaperone of Hsp90. It stabilizes the closed active form of Hsp90 and slows down its ATPase cycle by binding to the dimerized NTD of the chaperone Karagoz et al., 2011; Martinez-Yamout et al., 2006; Zuehlke and Johnson, 2010) . Among the identified co-chaperones of Hsp90, Aha1 is the only one that was reported to up-regulate the ATPase activity of the chaperone. During the chaperone cycle, Aha1's N-terminal domain binds to Hsp90's MD and induces a consequential conformation change in the MD of Hsp90. After that, the C-terminal domain of Aha1 interacts with Hsp90's NTD and promotes its ATPase activity Panaretou et al., 2002; Prodromou, 2016 Prodromou, , 2017 Zuehlke and Johnson, 2010) .
As mentioned earlier, the activity of Hsp90 is finely tuned by ATP/ADP and co-chaperones, and an efficient intervention of Hsp90's function could be achieved by interfering with one of the tuning steps in the working cycle of the chaperone. Multiple exogenous small molecules targeting the different structural domains of Hsp90 have been developed. They regulate Hsp90's function mainly via five ways: ATP competitive inhibitors, which block the access of ATP to the Hsp90's NTD (Prodromou, 2009; Roe et al., 1999; Sidera and Patsavoudi, 2014; Verma et al., 2016) ; inhibitors binding to the Hsp90's NTD and interfering with the interactions between Hsp90 and co-chaperones such as p23 and Cdc37 (Li et al., 2009 (Li et al., , 2018 Verma et al., 2016) ; compounds interacting with Hsp90's CTD and inhibiting its dimerization (Garg et al., 2016; Verma et al., 2016) ; allosteric activators binding to either the N-terminal domain or the interface region in between the middle domain and the C-terminal domain of Hsp90 (Bassanini et al., 2018; D'Annessa et al., 2017; Ferraro et al., 2019; Sattin et al., 2015; Yokoyama et al., 2015; Zierer et al., 2016; Zierer et al., 2014) ; and small molecules covalently bonding to the cysteine residue in the middle domain of Hsp90 Nakamoto et al., 2018; Zhang et al., 2018) . Among the reported chemical compounds targeting Hsp90, ATP competitive inhibitors form a dominant group, and quite a few compounds from this group are undergoing clinical trials for the treatment of cancer (Nabi et al., 2018; Sidera and Patsavoudi, 2014; Tatokoro et al., 2015) . Unfortunately, up to date, none of these inhibitors has been approved for cancer therapy. This could be at least partially attributed to the pro-survival heat shock response induced by the application of Hsp90 NTD inhibitors, which may compromise their therapeutic potential (Garg et al., 2016) . A large number of inhibitors have been developed to target Hsp90 NTD, but only one non-covalent inhibitor (gambogic acid) selectively binding to Hsp90b's middle domain has been reported (Yim et al., 2016) . Meanwhile, no known non-covalent modulator targeting the middle domain of Hsp90a, which is the most pronounced target for anti-cancer drug development among Hsp90 paralogs, has been discovered yet. Client protein recognition via proteinprotein interaction is the major function of Hsp90a's middle domain Prodromou and Pearl, 2003) . No binding pocket for small molecules has been experimentally identified for it. In this manuscript, the fragment-based lead compound discovery approach was applied to explore the possible binding cavity for exogenous modulators in Hsp90a's middle domain. Two active compounds were then obtained. The findings through conducting biophysical and biochemical assays demonstrate that the active compounds could bind to the middle domain of Hsp90a and allosterically modulate the function of the chaperone. More interestingly, these allosteric modulators act as artificial activating co-chaperones of Hsp90a and accelerate its ATPase activity in vitro. Finally, cellular assays were subjected to test the in vivo activities of obtained allosteric modulators. Anti-proliferation effects and down-regulation of representative Hsp90's clients were observed in breast cancer cell lines upon the application of these compounds.
that it is well structured in solution ( Figure 1A ). The backbone resonance assignments for Hsp90M in its free state have been reported (Park et al., 2011a) . These existing assignments are transferred onto our spectra and checked by 3D triple-resonance experiments including HNCA/HNCOCA, HNCO/HNCACO, and HNCACB/CACBCONH. Owing to the large size of Hsp90M, all of the 3D triple-resonance experiments were recorded by using TROSY (transverse relaxation optimized spectroscopy) scheme incorporated pulse sequences and 15 N, 13 C, and 70% deuterium labeled samples at 0.4 mM. Eventually, the resonances for 228 residues of a total number of 255 non-proline ones were assigned ( Figure 1A ). It is worth noting that the amide resonances for most of the amino acid residues in two regions including F349-K356 and K489-Y493 were entirely absent from the recorded spectra. The absence of these resonances suggests that they undergo slow conformational exchange in solution (Matsuo et al., 1999) . Secondary structural elements of Hsp90M were identified by comparing the chemical shift values of CO, CA, and CB atoms with those of the corresponding residues in randomly coiled structures ( Figure 1B ). This analysis revealed Hsp90M to be highly structured in solution with eight a-helices and six b-strands spanning its sequence, which indicates that the global fold of Hsp90M in solution state is similar to the folding pattern revealed by its crystal structure (PDB: 6KSQ) ( Figure 1C ). 
Hit Generation and Medicinal Chemistry Optimization
In a previous work, we have setup an NMR-based platform (nuclear magnetic resonance spectroscopybased platform) for fragment-based lead discovery, which includes a fragment library containing 539 compounds Figure S3A ). These data indicate that 1-E6 has a weak interaction with Hsp90's N-terminal domain. However, the interaction between 1-E6 and Hsp90's N-terminal domain shows no significant effect on 1-E6's binding to the middle domain of the chaperone ( Figure S3B ). There is no significant difference on the 1-E6-induced spectral changes of Hsp90's middle domain without or with the presence of its N-terminal domain ( Figure S3B ).
Subsequently, a medicinal chemistry campaign was conducted to optimize the hit compound 1-E6 (Figure S4 ). First, a global manipulation of 1-E6 was initiated, including replacement of the di-chloro substitution pattern with diverse mono-or multiple halogen or non-halogen substituents, changing the methylene linker with longer alkyl or with heteroatom-containing linkers, as well as substitution of the thiazol-2-amino with alkyl or acyl groups. This round of optimization led to identification of compound SOMCL-16-171 (Figure 2C) , showing more potency and specificity against Hsp90M. Meanwhile, a further focused optimization of the thiazole with various heterocycles yielded compound SOMCL-16-175 ( Figure 2C ), which showed even slightly higher potency. The binding of SOMCL-16-171 and SOMCL-16-175 to human Hsp90a and yeast Hsp82 (Hsp90a yeast homolog) was confirmed by ligand-detected CPMG and STD NMR data (Figures S5 and S6) . Besides, compared with 1-E6, both SOMCL-16-171 and SOMCL-16-175 are more potent Hsp90M modulators with enhanced CSP (chemical shift perturbation) effects upon binding ( Figures 2D and  2E ). The binding affinity of SOMCL-16-175 to Hsp90M was determined to be 804 mM ( Figure 2F ). Meanwhile, the weak binding observed for 1-E6 to Hsp90's N-terminal domain is almost fully or completely (SOMCL-16-175) abolished through compound optimization ( Figure S5 ).
SOMCL-16-171 and SOMCL-16-175 Are Allosteric Modulators of Hsp90a
Hsp90 contains three defined structural domains: an N-terminal ATP binding domain (NTD), a middle domain (MD) for client protein recognition, and a C-terminal domain (CTD) (Figure 3 ). The ATP binding and hydrolysis in Hsp90's N-terminal domain will trigger sequential conformation changes in both Hsp90's N-terminal domain and its middle domain, and these two domains work cooperatively in the chaperone cycle of Hsp90 (Prodromou, 2012 (Prodromou, , 2016 [Jacobs et al., 2006; Park et al., 2011b; Zhang et al., 2015] ), and two corresponding resonance peaks for each residue were observed ( Figure 3 Figure 3 and Table 1 ). However, the contributions of entropy (TDS) and enthalpy (DH) to the binding of ADP and AMPPNP to Hsp90a are modified by the presence of the compounds ( Figure 3 and Table 1 ). The ITC data suggest that, with the addition of the compounds, the entropy contribution (TDS) for ADP and AMPPNP (especially for ADP) binding are significantly enhanced (Table 1) . For example, when SOMCL-16-171 and SOMCL-16-175 were not or were pre-mixed with Hsp90NMD, the TDS values for ADP:Hsp90NMD system were determined to be À4.84, À0.41, and À1.16 kcal$mol À1 , respectively ( Table 1 ). The observed gain in entropy for AMPPNP/ADP:Hsp90NMD systems could be attributed to the conformational changes of Hsp90NMD and/or the perturbation of hydration network of the chaperone protein, which are induced by the binding of SOMCL-16-171 or SOMCL-16-175. Since the water/hydration network could be considered as a component of protein structure, the perturbation of hydration network caused by ligand binding is therefore intimately coupled to protein conformational changes (Biela et al., 2013; Chandler, 2005; Darby et al., 2019) . Therefore, the ITC data confirm that the binding of the active compounds to Hsp90a's middle domain does allosterically modulate the conformations of Hsp90a's N-terminal domain in solution.
Characterization of 4B ). The perturbed residues in Hsp90a upon the binding of SOMCL-16-171 and SOMCL-16-175 both localize to four fragments spanning N360-L363, D372-G387, K443-E451, and I522-E535, which are spatially close to each other ( Figure 4C ). And this suggests that these four regions modulate the binding of the compounds to Hsp90M. According to the backbone resonance assignments data, the region spanning F349-K356 of Hsp90M undergoes slow conformational exchange in solution and the resonances of the residues in this region are fully absent from the recorded NMR spectra. The slow conformational exchange in this gate-like fragment is expected to favor the recognition of the active compounds by Hsp90a's middle domain. The conclusion achieved by CSP analysis was further confirmed by the mutagenesis study results. Compared with the binding of SOMCL-16-175 to wild-type Hsp90M, its interactions with Hsp90M F349A and Hsp90M D350A mutants are almost fully abolished, and its interactions with Hsp90M L382A and Hsp90M K443E mutants induce less significant CSPs of the corresponding residues ( Figure S8 ). Meanwhile, the binding of SOMCL-16-175 to HSP90M Y528A mutant and its interaction with wild-type Hsp90M induce comparable CSPs of the representative residues ( Figure S8 ). The mutagenesis study data suggest that the a-helix spanning I522-E535 might not be involved in the direct binding of SOMCL-16-175 and the compound binding cavity in Hsp90M is composed of F349-N360, D372-G387, and K443-E451. The observed significant CSPs in the helical region spanning I522-E535 are most possibly from the conformational changes induced by the compound binding. To further define the binding cavity for SOMCL-16-175 and reveal the possible binding pose of SOMCL-16-175 in Hsp90M, molecular docking approach was applied. The docking grid was centered on the centroid of eight residues: Phe349, Leu363, Asp372, Gly387, Lys 443, Glu451, Ile522, and Glu535, which were chosen according to the CSP analysis data. The docking model was then obtained, and the binding pocket composed of F349-N360, D372-G387, and K443-E451 for SOMCL-16-175 in Hsp90M was confirmed ( Figure 4D ). According to the published literature, the binding pocket for exogenous small molecules in Hsp90a's middle domain identified by us is also found in Hsp90b's middle domain (Yim et al., 2016) .
After the identification of the binding sites of two compounds in Hsp90M, we then tested if the compound binding would allosterically modulate the ATPase activity mainly exerting by Hsp90a's N-terminal domain. As it has been reported, two fragments including K362-D372 and P395-I408 in Hsp90M are involved in the promotion of Hsp90's ATPase activity Prodromou, 2016) . P395-I408 is named as the catalytic loop, which promotes the ATP hydrolysis process by moving to an open active state and interacting with the g-phosphate of ATP through the conserved arginine residue in the fragment (R400 for Hsp90a, Figure 1C ) Prodromou, 2016) , whereas K362-D372 is spatially adjacent to the catalytic loop ( Figure 1C ) and is found to indirectly modulate the ATP hydrolysis process by its intimate interactions with the catalytic loop in Hsp90's middle domain (Hsp90a homolog in yeast) was monitored by acquiring 31 P spectra at different time points, and the representative spectra are shown in Figure 4E . At the reaction time point of 3 h after the initiation of the ATP hydrolysis, compared with the reaction system without the presence of SOMCL-16-175, higher concentrations of ADP and free phosphate ion and lower concentration of ATP were observed when SOMCL-16-175 was added (Figures 4 and S9) . And these data suggest that the ATPase activity of Hsp90a is promoted by the addition of SOMCL-16-175.
SOMCL-16-171 and SOMCL-16-175 Interact with Hsp90 in Cellular Context and Cause Cytotoxicity in Human Breast Cancer Cell Lines
Hsp90 plays important roles in the development of cancers by modulating the maturation of cancer-related client proteins including transcription factors and kinase (Garg et al., 2016; Prodromou, 2009; Sidera and Patsavoudi, 2014) . Besides, since Hsp90's chaperone cycle is intimately coupled to the sequential conformation changes induced by endogenous small molecules (ATP and ADP) and co-chaperones (p23, CDC37, Aha1), interfering with any one of the function-related structural states of Hsp90 would present modulation effects on its functional display, which might affect cell growth and proliferation. In this study, cellular thermal shift assay was used to confirm the interaction between SOMCL-16-171/SOMCL-16-175 and Hsp90 in cellular context. In this assay, cell extracts from three breast cancer cell lines, including MDA-MB-231, MCF7, and SKBR3, were pre-incubated with either one of SOMCL-16-171 and SOMCL-16-175 or 1% DMSO for 20 min. The mixture samples were then submitted to a parallel incubation lasting for 5 min at different temperatures ranging from 43 C to 67 C. The level of Hsp90 in the after-incubation samples 
SOMCL-16-175 Promotes the ATPase Activity of Hsp90 and Destabilizes Its Client Proteins
To unravel the potential molecular mechanisms underlying the modulation effects of SOMCL-16-175 on Hsp90, we analyzed the proteomic changes of MCF7 cells upon the presence of SOMCL-16-175 by the label-free quantification (LFQ)-based quantitative proteomic method ( Figure 6A ). Totally, we identified 51,393 peptide sequences, corresponding to 4,866 proteins, with an average of~30,000 peptide sequences and~4,500 proteins in each sample ( Figures S11A and S11B ). The LFQ intensities of identified proteins were . Continued (C) According to the CSP data shown in (A) and (B), one loop region spanning D372-G387 and two a-helices including K443-E451 and I522-E535 are identified to play key roles in the recognition of active compounds. These three regions are colored in red in both of the ribbon and the surface presentation of Hsp90M crystal structure (PDB: 6KSQ). The loop region spanning F349-N360, which undergoes conformational exchange in solution and is spatially close to D372-G387 and K443-E451, is colored in magenta.
(D) Expanded view of the possible binding mode of SOMCL-16-175 to Hsp90a's middle domain. Carbon, nitrogen, chlorine, and hydrogen atoms of the compound are colored green, blue, magenta, and white, respectively. The distances of the hydrogen bonds to SOMCL-16-175 are provided and indicated in black. Residues L382 and K443, which were selected for mutagenesis study, are highlighted and labeled.
(E) The 31 P NMR spectra data suggest that the application of SOMCL-16-175 promotes the ATPase activity of Hsp82 (Hsp90a yeast homolog). The ATP hydrolysis process catalyzed by Hsp82 was monitored by acquiring 1D 31 P spectra.
Superposition of 1D 31 P spectra of Hsp82:ATP (3 mM:1 mM) reaction system without (red) and with the presence of SOMCL-16-175 (500 mM, blue) acquired at the time point of 3 h after the initiation of the reaction.
distributed consistently and correlation coefficients among different samples are 0.97 on average, both demonstrating the high quality of our MS data ( Figures S11C and S11D ). Principle component analysis (PCA) of the proteomic data indicates a clear separation between the control group and the SOMCL-16-175-treated group ( Figure 6B ). By a global permutation-based FDR approach (Tusher et al., 2001 ), a total of 458 proteins (up, 180; down, 278) have been revealed to be regulated upon the addition of SOMCL-16-175 ( Figure 6C) . Notably, DNA function regulation and cell-cycle-related biological processes are over-represented in the down-regulated proteins ( Figure 6D ), suggesting the cell cytotoxicity of SOMCL-16-175. Quite a few of down-regulated proteins are known clients of Hsp90 and are summarized in Table  2 . Among the affected client proteins of Hsp90 (Table 2) , the levels of CDK1 (cyclin-dependent kinase 1) and CDK2 (cyclin-dependent kinase 2), which are two of the key players in cell-cycle control, were further tested by using immunoblot approach. Consistent with the proteomic data, significant down-regulation of CDK1 and CDK2 in response to SOMCL-16-175 treatment was observed ( Figures 6E and S12) . Meanwhile, CDK4 (cyclin-dependent kinase 4), one of kinase clients of Hsp90, also presents modest decrease in its cellular levels upon the addition of the compound ( Figures 6E and S12) . Interestingly, although the application of SOMCL-16-175 destabilizes Hsp90's client proteins (Table 2 , Figures 6E and S12 ), no significant heatshock response is triggered. Only a minor up-regulation was observed for the level of Hsp70 and Hsp90 upon the treatment of the compound ( Figures 6E and S12) . Overall, the observed down-regulation of Hsp90's client proteins suggests that the working cycle of the chaperone is finely tuned and the allosteric modulation of the function display of Hsp90 could be achieved by targeting its middle domain.
DISCUSSION
Hsp90 belongs to the chaperone superfamily and plays crucial roles in maintaining the stability and the activity of numerous client proteins, including kinases, transcription factors, and steroid hormone receptors. Owing to its function in controlling the cellular homeostasis of cancer-related proteins such as B-Raf (protein kinase encoded by the BRAF gene), CDK4, and v-src (tyrosine kinase encoded by the v-Src gene), Hsp90 has emerged as a promising target for anti-cancer drug development (Garg et al., 2016; Prodromou, 2009; Sidera and Patsavoudi, 2014 isoforms compromise their therapeutic potential (Garg et al., 2016; Vartholomaiou et al., 2016) . Therefore, developing non-ATP competitive compounds targeting Hsp90 deserves to be tested. In fact, quite a few of research works published during past several years indicate that the allosteric modulators binding to either the N-terminal domain or the interface region in between the middle domain and the C-terminal domain of Hsp90 might serve as new potential therapeutic opportunities (Bassanini et al., 2018; D'Annessa et al., 2017; Ferraro et al., 2019; Sattin et al., 2015; Yokoyama et al., 2015; Zierer et al., 2016; Zierer et al., 2014) . Different from the working mode of the canonical ATP competitive inhibitors of Hsp90, the allosteric modulators target the non-canonical binding sites of the chaperone and induce activation of its ATPase activity (D'Annessa et al., 2017; Roe et al., 2018; Sattin et al., 2015; Yokoyama et al., 2015; Zierer et al., 2014) . Meanwhile, although presenting accelerating effect on Hsp90's ATP hydrolysis activity, the application of these allosteric modulators would down-regulate the chaperoning function of Hsp90 for client proteins and cause cytotoxicity (D'Annessa et al., 2017; Ferraro et al., 2019; Sattin et al., 2015; Yokoyama et al., 2015; Zierer et al., 2014) . These results indicate that the ATPase activity does not fully correlate with the chaperoning activity of Hsp90 (Ferraro et al., 2019) . The delicately tuned conformational events and their associated time schedule are both required for the fully functional display of the chaperone. Therefore, both the ATPase inhibitors and the ATPase accelerators would down-regulate Hsp90's cellular activity through perturbing the timing of its chaperoning cycle.
Here in this manuscript, non-covalent allosteric modulators SOMCL-16-171 and SOMCL-16-175 targeting Hsp90a's middle domain were discovered by a combination use of experimental screening and medicinal chemistry-guided optimization. Compared with Hsp90a's N-terminal domain, which has a conserved ATP binding pocket shared by GHL-ATPase subfamily members (Dutta and Inouye, 2000) , Hsp90a's middle domain mainly functions in client protein recognition Prodromou and Pearl, 2003) and presents no known binding cavity for small molecules. Up to date, only active compounds covalently bonding to the cysteine residue in the middle domain of Hsp90a have been reported. Therefore, fragmentbased lead discovery approach, which has been proved to serve as a powerful tool for active compound discovery targeting allosteric binding sites and protein-protein interactions, was applied for Hsp90a's middle domain-targeted hit compound screening. Fortunately, one hit compound 1-E6 from a fragment pool containing 539 compounds was screened out (Figures 2 and S2 ). After that, medicinal chemistry-guided hit compound optimization was carried out and tens of compounds were synthesized. However, among these compounds, only SOMCL-16-171 and SOMCL-16-175 present enhanced CSP effects when binding to Hsp90M (Figure 2) . Besides, we found that the optimization attempt through fragment expansion would (Figure 3) . The CSP analysis data, the mutagenesis study results, and the generated docking model indicate that SOMCL-16-171 and SOMCL-16-175 bind to the pocket composed of one a-helix and two loops including K443-E451, F349-N360, and D372-G387 (Figures 4 and S8 ). And as revealed by the NMR data, loop region F349-K356 undergoes slow conformational exchange in solution, and the resonances for amino acid residues from F349 to K356 are totally absent in the recorded NMR spectra. The high flexibility of F349-K356 is expected to favor the recognition of the active compounds by Hsp90a's middle domain. Meanwhile, as revealed by the CSP analysis data, the binding of SOMCL-16-175 would induce long-range allosteric modulation effect on the hydrophobic region spanning K362-D372 of Hsp90a's middle domain (Figure 4 ). Since K362-D372 fragment has been reported to play a role in driving the function-related conformational changes of the catalytic loop in Hsp90's middle domain (Figure 1 ) , we then expect that the binding of SOMCL-16-171 and SOMCL-16-175 might modulate the ATPase activity of Hsp90a. This expectation is confirmed by the result of the in vitro ATP hydrolysis assay. With the addition of SOMCL-16-175, Hsp82 (yeast homolog of Hsp90a) presents an enhancement in its ATPase activity ( Figure 4 ).
As mentioned earlier, the developed allosteric modulators SOMCL-16-171 and SOMCL-16-175 could accelerate the ATPase activity of Hsp90 by binding to the pocket composed of F349-N360, K443-E451, and D372-G387 in the middle domain of the chaperone ( Figure 4 ). As it has been known, the co-chaperone Aha1 could stimulate the ATPase activity of Hsp90. The working mode for Aha1:Hsp90 system includes the binding of Aha1's N-terminal domain to Hsp90's middle domain and the nucleotide-dependent binding of Aha1's C-terminal domain to Hsp90's N-terminal domain, which occur in a sequential manner (Retzlaff et al., 2010) . A very recent study indicates that the phosphorylation on Y313 of Hsp90's middle domain, which has been reported to promote the recruitment of Aha1 (Xu et al., 2012) , would enhance the formation of a transient complex in which both the N-terminal and C-terminal domains of Aha1 bind independently to distinct surfaces of the middle domains in opposing Hsp90 protomers (Xu et al., 2019) . Besides, the perturbed residues in the middle domain of Hsp90 Y313E (a phosphomimetic mutation) mutant upon the binding of Aha1 are identified to be I361, I370, I378, I385, I445, I491, I494, and I519 (Xu et al., 2019) . Since a few of these residues fall into the SOMCL-16-171 and SOMCL-16-175 recognition regions including K443-E451 and D372-G387 in Hsp90's middle domain, binding of the compounds to the chaperone might potentially interfere with the recruitment of Aha1. However, owing to the significant difference in the binding affinities for Aha1 and the developed compound SOMCL-16-175 to Hsp90, which are 13 (Xu et al., 2012) and 804 mM, respectively, the possible interfering effects are not observable in this study. An allosteric modulator with significantly enhanced binding affinity to the identified pocket in Hsp90's middle domain could serve as a probe molecule to answer the aforementioned question and provide more information for a further understanding of the chaperoning cycle of the chaperone.
After the in vitro characterization of the interactions between Hsp90a and the active compounds targeting Hsp90a's middle domain, in vivo assays including cell viability assay, colony formation experiment, and mass spectroscopy-based proteomics analysis were carried out to test the cellular activities of the compounds and reveal the underlying molecular mechanisms coupled to their in vivo activities. Not surprisingly, both SOMCL-16-171 and SOMCL-16-175 cause cytotoxicity in human breast cancer cell lines MDA-MB-231, MCF7, and SKBR3 (Figures 5 and S10 ). Besides, we found that, among two active compounds, SOMCL-16-175 shows stronger cytotoxicity than SOMCL-16-171 (Figures 5 and S10 ). This is consistent with their in vitro characterization data. The binding of SOMCL-16-175 would induce a much larger Tm shift of Hsp90a (Figures 3 and S7) . Since SOMCL-16-175 presents stronger cytotoxicity in breast cancer cell lines, a further proteomics study was applied to investigate the potential working mechanisms linking to the anti-proliferation activity of this compound. Upon the treatment of SOMCL-16-175, the down-regulation of the cell-cycle process in MCF7 cell line was revealed by the quantitative proteomic analysis and the decreased levels of multiple key players involved in the cell-cycle pathway were observed ( Figure 6 ). More interestingly, both the proteomic analysis and the immunoblot data demonstrate that no significant heat-shock response is triggered by the treatment of SOMCL-16-175 (Figures 6 and S12 ). Although the modest binding of the compound to Hsp90 might potentially contribute to this observation, it is still an encouraging finding and deserves to be investigated further. To achieve an exclusive conclusion, allosteric modulator with stronger binding affinity to Hsp90a's middle domain needs to be developed and evaluated.
Limitations of the Study
In this study, two allosteric modulators (SOMCL-16-171 and SOMCL-16-175) of Hsp90a were developed. However, these two compounds only present modest binding capabilities to the middle domain of the chaperone. And at least partially due to the low binding affinities, no high-resolution complex structures for Hsp90M:SOMCL-16-171 and Hsp90M:SOMCL-16-175 were solved, which would make a further compound optimization derived from SOMCL-16-171/SOMCL-16-175 less efficient.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
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Synthesis of compound SOMCL-16-175

2-(2,4-Dichlorophenyl)-N-methoxy-N-methylacetamide (2-1):
To a solution of 2-(2,4-dichlorophenyl)acetic acid (205 mg, 1 mmol) in CH2Cl2 were added N,O-dimethylhydroxylamine (1.3 equiv), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 1.3 equiv) and 1-hydroxybenzotriazole (HOBT, 1.3 equiv).
Di(isopropyl)ethylamine (DIPEA, 3 mL) was added. The mixture was stirred at room temperature for 2 h, and then concentrated. The residue was purified with column chromatography to yield the title compound as colorless oil in 80% yield. 
N-(5-(2,4-Dichlorobenzyl)-1H-imidazol-2-yl)acetamide (2-4):
A solution of 2-3 (33 mg，0.118 mmol) in DMF at 0 o C was added the solution of Nacetylguanidine (2 equiv) in CH2Cl2 (1 mL). The mixture was stirred at room temperature overnight. Then water was added, and the mixture and was extracted with ethyl acetate, washed with brine, and dried over MgSO4. After filtration and concentration, the residue obtained was purified with column chromatography to yield the title compound as yellow solid in 27% yield. 134.62, 133.84, 132.89, 131.49, 129.53, 127.56, 124.19, 109.33, 29.71 Escherichia coli and purified by using a combination of affinity chromatography and size exclusion chromatography on an FPLC system. Hsp90 273-554 was cleaved from its His-tag during elution from Ni-NTA resin by using thrombin. Hsp90 NM∆ with its N-terminal domain isotope labelled was prepared by following the reported protocol with a moderate modification (Freiburger et al., 2015) . Hsp90 NM∆ with its N-terminal domain isotope labelled was synthesized by using two protein samples Hsp90 cryoprobe at 25 ℃. The spectra were processed by using NMRPipe (Delaglio et al., 1995) and analyzed with CARA (Keller, 2004) and Sparky (Kneller and Kuntz, 1993 
where ∆ avg donates the observed chemical shift change, δTOT is the chemical shift difference between free and complexed protein, n is the binding stoichiometry, LT is the concentration of titrant protein and PT is the total concentration of analyte protein (Fielding, 2007) .
Crystal structure determination
Crystals of Hsp90α's middle domain were obtained by using hanging drop vapor diffusion method in a solution containing 0.5 M ammonium sulfate, 29.5% (w/v) polyethylene glycol 3350 and 5% glycerol (pH 8.5) at 4 ℃. The final concentration of Hsp90M used in the crystallization was 0.12 mM. The crystals obtained were cryo-protected in the crystallization buffer containing 20% (v/v) glycerol and flash cooled in liquid nitrogen. X-ray diffraction data were collected at beamline BL17U1 at the Shanghai Synchrotron Radiation Facility (Wang et al., 2018) . The data were processed with HKL3000 (Minor et al., 2006) . The structure was solved by molecular replacement using the program CCP4 with a search model of PDB code 1HK7 (Bailey, 1994; . The models were built using coot and refined with a simulated-annealing protocol implemented in the program PHENIX (Adams et al., 2002; Emsley and Cowtan, 2004) . Data collection and refinement statistics of the solved structure was shown in Table S1 .
Fragment-based active compound discovery
Hit fragment compound screening with Hsp90α's middle domain as the target were carried out by following our previously reported protocol . In the first round of screening, 200 M grouped fragment compound mixtures without or with the presence of 5 M Hsp90M were dissolved in phosphate buffer (20 mM NaH2PO4/Na2HPO4, 100 mM NaCl and 2% DMSO in D2O) and used in ligand-observed CPMG and STD spectrum acquisition. The potential hit compound candidates were then subjected to a second-round of screening by using CPMG and STD NMR experiments. 200 M single potential hit compound without or with the presence of 5 M Hsp90M were used in the second-round of screening. All of the ligand observed CPMG and STD NMR experiments were acquired at 25 °C on Bruker 600 MHz NMR spectrometer equipped with a cryogenically cooled probe.
General synthetic approach for SOMCL-16-171 and SOMCL-16-175
The general synthetic approach for compounds is summarized in scheme 1. The synthesis of SOMCL-16-171 commenced from the condensation of thio-urea with DMF-DMA followed by cyclization with 2-bromo-1-(2,4-dichlorophenyl)ethanone. The synthesis of SOMCL-16-175 was started from 2-(2,4-dichlorophenyl)acetic acid, which was first transformed to the ketone intermediates 2-2 through forming the Weinreb amide 2-1 followed by treatment with 
Molecular docking
The crystal structure of Hsp90α's middle domain (PDB: 6KSQ) was prepared using the Protein Preparation Wizard implemented in the Schrö dinger suite (Sastry et al., 2013) . This procedure added hydrogen atoms and missing side chains of residues. The orientation of polar hydrogens and the protonated states of the receptor were then optimized. The overall structure was refined using OPLS3 force field (Harder et al., 2016) with harmonic restraints on heavy atoms. The 3D structure of SOMCL-16-175 was generated and optimized using the Ligprep tool of the Schrö dinger suite, and the docking of SOMCL-16-175 to Hsp90M was performed with the Induced Fit Docking (IFD) tool. The detailed protocol of IFD tool can be found as previously published (Koldso et al., 2010) . The docking grid was centered on the centroid of eight residues: Phe349, Leu363, Asp372, Gly387, Lys 443, Glu451, Ile522, and Glu535. These residues were chosen according to the NMR studies. The following docking simulation was performed with default settings except that the extra precision (XP) mode was used in the last docking round. The final pose was selected from the top-scoring conformations.
Isothermal titration calorimetry measurements
All ITC measurements were performed at 30 ℃ by iTC200 calorimeter (GE Healthcare) in an ITC buffer (20 mM Tris, 75 mM NaCl, 6 mM MgCl2 and 1 mM β-mercaptoethanol, pH 7.4) while stirring at 800 rpm. Hsp90 NM∆ protein samples were premixed with DMSO or either with one of two compounds (ten-fold molar excess of SOMCL-16-171 or SOMCL-16-175). Pretreated protein was diluted with the ITC buffer to 50 μM, and ADP or AMPPNP was diluted with the ITC buffer to a final concentration of 1 mM. The final concentration of DMSO in the reaction buffer is 2.5% of the total volume. The titrations were performed using an initial injection of 0.4 μL followed by 19 identical injections of 2 μL ADP or AMPPNP to the cell, and last three data points were averaged to account for the heat of dilution. Data were analyzed by using the program Origin 7.0.
Thermal shift assay
Protein thermal shift experiments were performed on a 7500 fast real-time PCR system (ABI, United States). Each reaction system contains 5 × SYPRO Orange, 10  protein sample and 1 mM SOMCL-16-171 or 500  SOMCL-16-175 dissolved in 20 L of thermal shift assay buffer (20 mM Tris, 75 mM NaCl and 1 mM β-mercaptoethanol, pH 7.4). The mixture samples were heated from 25 ℃ to 99 ℃ at 1% Ramp rate, and the melting curves were processed by using Protein Thermal Shift software 1.3.
ATP hydrolysis assay
The ATP hydrolysis process catalyzed by Hsp82 (Hsp90α yeast homolog) was monitored by recording 31 P NMR spectra on Bruker 500 MHz NMR spectrometer equipped with a liquid nitrogen cooled cryoprobe at 25 ℃. The reaction systems containing 3 μM Hsp82 and 1 mM ATP without or with the presence of 500 μM SOMCL-16-175 or 200 μM Geldanamycin (GA)
were dissolved in reaction buffer (100 mM Tris, 20 mM KCl, 6 mM MgCl2, pH 7.4) and incubated at 37 ℃. The 31 P NMR spectra were acquired right after a three hour incubation.
Cellular thermal shift assay（CETSA）
Cellular thermal shift assay was conducted according to the protocol as reported (Molina et al., 2013) . MDA-MB-231, MCF7 and SKBR3 cells were harvested with PBS buffer and lysed by subjecting to three freeze-thaw cycles. Then, the cell lysates were mixed and incubated quantification (LFQ) was chosen for proteomic quantification using the default parameters. The function of "Match between runs" was used to reduce missing values in proteome quantification with a matching time window of 0.7 min and an alignment time window of 20 min.
Carbamidomethyl cysteine was searched as a fixed modification. Oxidized methionine and protein N-term acetylation were set as variable modifications. Enzyme specificity was set as trypsin. The maximum missing cleavage site was set as 2. The tolerances of first search and main search for peptides were set at 20 ppm and 4.5 ppm, respectively. The minimal peptide length was set at 7. False discovery rates (FDRs) of peptide and protein were set with the cutoffs not greater than 1%.
LFQ intensity was used for proteomic data analysis. All analysis steps were conducted in Persus and R softwares. Missing values were imputed by method of normal distribution imputation in Perseus. Principal component analysis (PCA) was conducted using factoextra package in R. Differently expressed proteins were analyzed using a global permutation-based FDR approach implemented in Perseus. GO biological process enrichment analysis was performed using Fisher's exact test in Perseus.
Immunoblot analysis
The MCF7 cells were harvested with RIPA (P00013C, Beyotime, China) lysis buffer sitting on the ice after treated with 0.1% DMSO, 0.1 M Geldanamycin or 35 M SOMCL-16-175 for 48 h. The cell debris was removed by centrifugation at 12000 rpm for 15 min, and the supernatant was collected. Protein concentrations for all of the samples submitted to western blot analysis were measured by using the Bradford method (Bradford kit, P0006C, Beyotime, China), and samples containing equal amounts of total protein were loaded for SDS-PAGE gel electrophoresis. The protein samples in polyacrylamide gel were then transferred onto 0.22 M PVDF membrane (Millipore, United States) under a constant current running for 3 h. The membranes were blocked by using 5% defatted milk and incubated with primary antibodies (CDK1, CDK2, CDK4, Hsp70, Hsp90 and -actin) in 4 ℃ for 16 h. After removing the primary antibodies, the membranes were further incubated with the secondary antibody (HRPconjugated anti-mouse or HRP-conjugated anti-rabbit antibody) at room temperature for 2 h.
Finally, chemiluminescent HRP substrate was applied to visualize specific proteins in the
